Login / Signup

Risk factors for relapse after discontinuation of tenofovir or entecavir in hepatitis B e antigen-negative patients.

Cigdem MermutluogluOmer KarasahinMustafa Kemal Celen
Published in: Hepatology forum (2024)
Among HBeAg-negative CHB patients who achieved a virological and biochemical response to long-term antiviral therapy, those aged 42 years and older, those with high fibrosis scores before treatment, and those who used TDF before treatment cessation should be closely monitored for relapse, especially in the first 12 months after stopping NA treatment.
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • peritoneal dialysis
  • hiv infected
  • free survival
  • patient reported outcomes